Purpose Metabolic imaging using [ 18 F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for FDG. The majority of B cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging. We previously developed PET tracers based on the humanised anti-CD20 antibody obinutuzumab (GA101). Preclinical studies showed that the smallest bivalent fragment, the cys-diabody (GAcDb, 54.5 kDa) with a peak uptake at 1-2 h post-injection and a biological half-life of 2-5 h, is compatible with short-lived positron emitters such as fluorine-18 ( 18
Introduction
Positron emission tomography (PET) using [ 18 F]fluorodeoxyglucose (FDG) combined with computed tomography (CT) has become the standard clinical imaging application in lymphoma [1] . FDG PET/CT plays a crucial role in staging [2] [3] [4] and response evaluation in Hodgkin (HL) and nonHodgkin lymphomas (NHL) [5, 6] . While metabolic imaging facilitates noninvasive imaging of lymphoma, the only conclusive diagnostic method for HL and NHL is highly invasive tissue biopsies that delineate the genetic and phenotypic differences between lymphoma types [7] .
Further limitations of FDG include nonspecific uptake in nonmalignant tissues (e.g., inflamed tissues) and in different cell types of the tumour microenvironment with high metabolic activity (e.g., immune cells, stromal cells) [8] . Malignant lymphomas often exist as disseminated disease with single or confluent tumours presenting a wide range of volumes and heterogenous uptake [3, 9] . Some forms of NHL show low FDG avidity, e.g., MALT marginal zone lymphoma, small lymphocytic lymphoma and cutaneous B cell lymphoma [2, 7] .
ImmunoPET, utilising the specificity of antibodies, could provide additional phenotypic information regarding the presence or modulation of a B cell specific target, and has the potential to improve diagnosis, therapy selection and patient stratification. The B cell antigen CD20 is expressed on B lymphocytes, with minimal or no expression on early pre-B cells, plasma cells or other normal cells. CD20 expression on B cell malignancies is an important biomarker and therapy target, as evidenced by the clinical success of anti-CD20 monoclonal antibodies (mAbs) rituximab, ofatumumab, obinutuzumab and the radioimmunotherapeutic ibritumomab tiuxetan [10, 11] . Anti-CD20 mAbs have also shown clinical benefits in the treatment of the autoimmune disorder rheumatoid arthritis (RA) and are in clinical trials for systemic lupus erythematosus (SLE) and multiple sclerosis (MS) [12] .
While radiolabeled full-length IgGs have been successfully used for PET imaging [13, 14] , their long plasma half-life and their therapeutic activity are disadvantageous for both prompt and repeated imaging. We previously developed CD20-specific immunoPET tracers using obinutuzumab (GA101) based antibody fragments radiolabeled with zirconium-89 ( 89 Zr) or iodine-124 ( 124 I) and showed antigen specific targeting of malignant and endogenous B cells in vivo [15] . The smallest bivalent fragment, the cys-diabody (GAcDb, 55 kDa), presents a suitable compromise between tumour uptake (peak uptake 1-2 h) and blood clearance (t 1/2 2-5 h) that aligns with the half-life of 18 F (t 1/2 110 min), the most broadly used PET radionuclide [16] . 18 F-radiolabeling of GAcDb could enable same-day imaging and lower radiation exposure compared with the longer-lived 124 I (t 1/2 4.2 days) and 89 Zr (t 1/2 3.3 days). Furthermore, 18 F has almost ideal imaging properties, with a high positron yield (97%), low mean positron range (0.5 mm) and no simultaneous gamma ray emission that would increase background. Although 18 F is readily available in most radiopharmacies, the synthesis of prosthetic groups and the generation of 18 Flabeled antibody fragments can require elaborate procedures under time constraints caused by the short half-life. These challenges can be overcome by automated chemistry stations that enable the synthesis of prosthetic groups for radiofluorination of peptides and proteins [17, 18] [20, 21] , scFv [22] and nanobodies [23, 24] . Alternatively, the thiol-reactive labelling
can be used for site-specific conjugation to cysteine residues [25] , as shown for affibodies [26] , and epidermal growth factor (EGF) [27] .
For preclinical imaging evaluation of the 18 F-labeled antihuman CD20 GAcDb, a major consideration is the selection of a murine model of lymphoma. Most common are human xenograft models, based on homogenous cell lines, and implanted subcutaneously into immunodeficient mice. However, these xenograft models do not represent lymphomas that directly arise from immune cells, and they lack the complex interactions between cancer and the immune system that are of great interest in therapeutic and imaging studies. Transgenic models of lymphoma (e.g., altered c-Myc and Bcl-2 proteins) represent more realistic disease models [28, 29] , but are not useful for studying antibodies targeting human antigens.
In this study, we used a transgenic mouse model expressing human CD20 (hCD20TM, BALB/c x hCD20) specifically on mature B cells ( [30] . For a more physiologically and clinically relevant lymphoma model we used a syngeneic B cell lymphoma cell line transduced to express human CD20 (A20-hCD20) [31] . When injected intravenously into hCD20TM, the disseminated lymphoma grows nodular lesions primarily in the liver and spleen, mimicking the natural development of an aggressive human lymphoma (diffuse large B cell lymphoma, DLBCL) [32] . This lymphoma model enables imaging in the context of normal tissue expression of hCD20. Serial imaging using [ 18 F]FDG PET/CT followed the next day by [ 18 F]FB-GAcDb immunoPET/CT was conducted on mice with limited or extensive disease and on mice injected with antigen negative A20 cells as control. [25] were generated using the ELIXYS automated radiosynthesizer (Sofie Biosciences) [33] . Radiochemical purity was confirmed to be >95% by radio-HPLC, and radiochemical identity was confirmed in analytical HPLC by comparison with co-injected standard.
Materials and methods

Radiosynthesis
Radiolabeling of GAcDb
Cloning, production and purification of the obinutuzumabbased cys-diabody GAcDb has been described previously [15] .
For random labelling to lysine residues, [ . Excess prosthetic groups were separated from the conjugate using Micro Bio-Spin size exclusion columns (Bio-Rad) pre-blocked with PBS, 1%FBS. Labelling efficiency and radiochemical purity were analysed using ITLC strips (for monoclonal antibody preparation, Biodex Medical Systems) with saline as solvent (Wizard 3′ 1480 Automatic Gamma Counter, Perkin Elmer). The immunoreactive fraction of radiolabeled GAcDb was determined by incubation with excess antigen expressing cells (A20-hCD20) and control cells (A20) for 1 h at 22°C as described previously [15] .
Syngeneic disseminated B cell lymphoma model
All procedures performed in studies involving animals were in accordance with the ethical standards of the University of California Los Angeles (UCLA) Animal Research Committee. Murine A20 BALB/c B cell lymphoma line (ATCC) and A20 cells transduced with a lentivirus encoding the human CD20 gene (A20-hCD20, clone R2D2) [34] were cultured in RPMI1640 supplemented with 10% FBS and 50 μmol/L 2-mercaptoethanol (Life Technologies). Human CD20 transgenic mice (hCD20TM), a kind gift from Mark Shlomchik, Yale University, have been described previously [30, 34] and were backcrossed onto BALB/c backgrounds and genotypes confirmed by PCR (Fig. S1 ). A20 or A20-hCD20 cells were washed three times using Hank's Balanced Salt Solution (HBSS) buffer and injected intravenously (lateral tail vein, 1 × 10 6 cells/100 μL HBSS).
ImmunoPET/CT imaging, ROI analysis and biodistribution
PET imaging (Inveon, Siemens) was performed under 2% isoflurane anaesthesia followed by a CT scan (MicroCAT, Siemens). Optional FDG-PET (10 min static scan) was conducted 24 h prior to immunoPET imaging, using 3. ]FBEM-GAcDb. One-or two-hour dynamic PET acquisitions were followed by ten minute static scans at 2, 4 and 6 h post injection (p.i.). PET images were reconstructed using maximum a posteriori (OSEM MAP) algorithm, and PET and CT images are presented as maximum intensity projection (MIP) overlays. AMIDE software was used for image analysis [35] . For quantitation of the PET signal in specific organs, 3D regions of interest (ROI) were drawn and the mean voxel value was converted to %ID/cc ROI using the decay corrected injected dose and an empirically determined cylinder factor for 18 F. Ex vivo biodistributions were performed by weighing and gamma counting tissues and calculating %ID/g values based on standards containing 1% of the injected dose.
Statistical analysis
Data values are reported as mean ± SD unless indicated otherwise. Ex vivo biodistribution values are depicted as box-andwhiskers (min to max) graphs. For statistical analysis multiple t-tests (Holm-Sidak method, GraphPad Prism) were performed.
Results
Radiolabeling of GA101 cys-diabody (GAcDb)
GAcDb was successfully 18 F-radiolabeled using two different approaches. For random labelling, the amine reactive prosthetic group N-succinimidyl-4-[ GAcDb (Fig. 1d) 18 F]FBEM-GAcDb (15 μg) were injected i.v. into hCD20TM, and dynamic PET scans (1-2 h) followed by 10-min static scans of the same mouse at 2 and 4 h post injection (p.i.) were acquired (Fig. 2) . [ 18 F]FBGAcDb (Fig. 2b) showed rapid targeting to the B cell containing spleen with activity visible as early as 10 min p.i. and peaking around 30-60 min p.i. The signal in the kidneys and the bladder increased over time indicating clearance/excretion of the tracer primarily through the kidneys and into the urine. Activity in the kidneys was highest around 1 h p.i. and decreased continuously while antigen-specific retention in the spleen was more steady, resulting in high-contrast PET images at 4 h p.i.
In comparison, [
18 F]FBEM-GAcDb (Fig. 2c) showed earlier (5 min p.i.) and higher target specific accumulation in the spleen peaking at 30 min p.i. followed by a steady decrease of the radioactivity signal. The signal in the heart (estimating the activity in the blood pool) decreased visibly from 10 min p.i. on, indicating a more rapid blood clearance compared with HCD20TM imaged using the metabolic tracer [
18 F]FDG showed only non-specific background activity in the Harderian glands, heart, kidneys, intestines and bladder (Fig. 3a) . In contrast, both anti-CD20 immunoPET tracers successfully visualised the normal tissue distribution of hCD20 in spleen and lymph nodes (rescaled images in Fig.  3b and c) . Notably, the smallest (popliteal) lymph nodes visible in the immunoPET scans are only about 1 mm 3 in size. Although the signal in the spleen at 4 h p.i. is comparable between the two tracers, the remaining activity in the intestines for [ 
F-radiolabeling chemistry affects tracer biodistribution and excretion
Quantitative region of interest (ROI) analysis of the immunoPET scans was conducted for both tracers (Fig. 4a  and c) . For the randomly labeled [ 18 F]FB-GAcDb, peak uptake in the target organ (spleen,~18%ID/g ROI ) was reached between 1 and 2 h p.i. followed by slow decrease of activity thereafter. Activity in organs of clearance (kidneys) was highest around 1 h p.i. at 20%ID/g ROI . Highest target-tobackground ratio is achieved at later time points (> 2 h p.i.) when activity has sufficiently cleared from the blood (heart) and the kidneys (5-10%ID/g ROI ). The tracer half-life as calculated from the blood curve is t 1/2(β) 68.8 min.
In contrast, the site-specifically labeled [ 18 F]FBEMGAcDb reached higher uptake in the spleen (38%ID/g ROI ) at earlier time points. Activity in organs of clearance (kidneys) peaked around 0.5 h p.i. at 15%ID/g ROI . Therefore, to achieve high contrast images without obstruction by nonspecific activity in the GI tract, [ (6 h p.i., n = 4) confirmed the spleen as the organ with the highest uptake ( Fig. 4b and d , Table S1 ). We did not observe a difference in %ID/g in the liver, although higher remaining activity in the intestines (GI tract including contents) at 6 h p.i. was confirmed for [ Murine syngeneic B cell lymphoma cells (A20) engineered to express human CD20 (A20-hCD20) with an antibody binding capacity of~45,000/cell (Fig. S2) were implanted into immunocompetent transgenic mice (BALB/c x hCD20). Intravenous injection of A20 lymphoma cells results in the dissemination of cells to the liver, and macroscopic examination showed prominent nodules on the liver surface after approximately 2-3 weeks (Fig. 5 ). Mice were grouped as 'limited disease' with multiple tumour lesions visible in the liver, but without a change in average liver weight (1.55 ± 0.3 g, n = 4) and 'extensive disease' with significant tumour lesions visible and enlargement of livers (3.0 ± 0.7 g, n = 6). Target tissue uptake was compared to control groups of non-lymphoma bearing hCD20TM (n = 7) and hCD20TM injected with CD20-negative A20 (limited disease, liver weight: 1.32 ± 0.07 g, n = 4).
[ (Fig. 5a) . [ 18 F]FB-GAcDb shows no nonspecific uptake in antigen negative metastases in the liver but targets CD20-expressing B-cells in the spleen and lymph nodes (Fig. 5a ). CD20-positive (A20-hCD20) F]FDG uptake is visible in the liver but is somewhat diffuse and obstructed by background activity in the heart and the kidneys (Fig. 5c) . [ 18 F]FB-GAcDb immunoPET images of the same mice show distinct antigenspecific uptake in the liver nodules. CD20-positive lymphoid organs also show specific tracer uptake while less nonspecific background activity is seen in other tissues.
Ex vivo biodistribution confirmed the spleen as the organ with the highest uptake (17.7 ± 4.3%ID/g) in hCD20TM (Fig. 6, Table S2 ). Average uptake in the normal liver was 1.5 ± 0.5%ID/g. In CD20-positive lymphoma bearing mice (A20-hCD20), uptake in the liver was significantly higher for mice with both limited or extensive disease (2.4 ± 0.2%ID/g, p = 0.0037 and 4.8 ± 1.2%ID/g, p < 0.0001, respectively) and was not significantly different in mice with antigen-negative disease (A20, 1.1 ± 0.2%ID/g). This was further corroborated by the significantly increased total uptake in the liver of 3.7 ± 0.7%ID (p = 0.0013) for limited disease and 14.7 ± 5.6%ID (p < 0.0001) for extensive disease compared with 1.8 ± 0.7%ID in hCD20TM and 1.4 ± 0.3%ID in antigen negative disease.
At the same time, the uptake in the spleen decreased in mice with limited and extensive disease (10.7 ± 3.0 and 6.9 ± 2.0%ID/g, respectively) compared with hCD20TM, presumably due to the antigen sink effect caused by higher tumour burden. In contrast, the lower uptake value (9.6 ± 2.8%ID/g) in the spleen of mice injected with CD20-negative A20 lymphoma cells is likely caused by increased mass due to tumour growth in the spleen (hCD20TM: 0.11 ± 0.01 g; A20: 0.14 ± 0.05 g; A20-hCD20 lim: 0.15 ± 0.04 g; A20-hCD20 ext.: 0.22 ± 0.07 g).
Discussion
Metabolic imaging by [ 18 F]FDG PET has become the clinical standard in the assessment of patients with aggressive nonHodgkin lymphoma (NHL) both for initial diagnosis and for response after therapy. The most prevalent subtypes of aggressive NHL (DLBCL, MCL, FL) are usually FDG-avid, and FDG PET/CT can lead to upstaging in 10-20% of cases compared with CT only [2] , while low grade indolent lymphoma can show little to no uptake of FDG. A molecular imaging application that is specific for a tumour associated antigen could facilitate visualisation of FDG-inert lymphomas and/or complement FDG PET with phenotypic information. We previously developed a small bivalent antibody fragment (cys-diabody, GAcDb) based on the humanised, therapeutic, human CD20-specific antibody obinutuzumab (GA101), and confirmed specificity for B cells in vivo [15] . In this work, we successfully radiolabeled GAcDb using prosthetic groups [ A major motivation for combining 18 F with the diabody format is the rapid clearance of the tracer, resulting in high contrast immunoPET images at early time points; thus, enabling same-day-imaging. At the same time, minimisation of radiation dose and exposure for the patient is a main feature of short-lived radionuclides, particularly with an almost pure positron emitter such as 18 F. The impact of the radiolabeling method on the biodistribution and pharmacokinetics of GAcDb was evaluated in a human CD20 transgenic mouse model (hCD20TM). Both labelling strategies were executed with similar reaction times and resulted in comparable specific activities; however, the random labelling to lysine residues using [ 18 F]SFB bears the risk of labelling lysines located at or in the antigen binding sites. In contrast, the site-specific conjugation using [ Zr-labeled GAcDb [15] [37, 38] . To prevent long residence times of radiometabolites and renal toxicity, tubular reabsorption can be blocked by infusion of basic amino acids (lysine, arginine) or polygelines (e.g., Gelofusine®) [39] [40] [41] . Importantly, no defluoridation of 18 F-labeled GAcDb was observed for either conjugation method, as there is no bone uptake visible in the PET scans at any time. In this study, the smallest detectable structures (popliteal lymph nodes) in the hCD20TM were approximately~1 mg in size, containing~10 6 cells, with 30% B cells in the mouse lymph node [42] . While normal human B cells express around 100,000 CD20 molecules per cells, the transgenic mouse model is described as expressing about 7-fold lower CD20 levels per cell compared to B cells from human peripheral blood [30, 43] . This would suggest that [ 18 F]FB-GAcDb immunoPET is able to detect an estimated 300,000 cells with an antigen density of~15,000 CD20/cell in a mouse lymph node.
The syngeneic and immunocompetent lymphoma model (A20 in BALB/c mice) has been used extensively for preclinical evaluation of lymphoma therapies because it resembles the invasion course of aggressive human lymphoma (liver, spleen and mesenteric lymph nodes) [44] [45] [46] [47] . Furthermore, a study by Chaise et al. evaluated [ 18 F]FDG PET for early detection of therapy response in the A20 model, showing high level FDG uptake and the feasibility of non-invasive monitoring of A20 tumour growth, especially for intra-abdominal nodules that are poorly accessible to examination [32] .
In the present study, we used A20 lymphoma cells transfected to express hCD20 in hCD20 transgenic BALB/c mice to show the practicability and relevance of lymphoma imaging in context of the endogenous B cell compartment. The influence of tumour mass and antigen sink on the biodistribution and uptake values of the radiolabeled antibody fragment (protein dose 15 μg) was more pronounced in mice with extensive A20-hCD20 lymphoma, with liver uptake significantly higher and spleen uptake lower compared with healthy hCD20TM or limited disease. These results indicate that anti-CD20 immunoPET could be a valuable tool for determining dosimetry, e.g., for anti-CD20 radioimmunotherapy or other CD20 targeting therapies.
The ability to monitor disseminated disease in immunocompetent mice is crucial for evaluating lymphoma therapies because the tumour microenvironment in disseminated disease can differ from subcutaneous models of lymphoma and plays an important role in the immune response induced by therapy [48] . While [ Furthermore, anti-CD20 immunoPET could detect down regulation or loss of cell surface CD20, which might be one of several mechanisms of acquired resistance to rituximab. Several groups report a CD20-negative phenotypic switch after rituximab therapy [49] . Hiraga et al. showed that CD20 mRNA and protein expression can be restored and therefore seems regulated by epigenetic mechanisms [50] . Other groups have shown down-regulation of CD20 protein surface expression by FcRIIb-mediated internalisation or removal of antigen/antibody complexes by monocytes (trogocytosis) [51, 52] .
In conclusion, we presented novel 18 F-labeled anti-human CD20 antibody fragments for same-day immunoPET and showed their ability to detect both endogenous B cells and malignant B cells in vivo. Because GAcDb is based on the humanised, therapeutic antibody obinutuzumab it has potential for clinical translation for imaging in B cell lymphoma. F]FB-GAcDb, 4 h p.i. Ex vivo biodistributions were conducted after the last scan for each group: hCD20TM (n = 7), A20-hCD20 limited disease (n = 4), A20-hCD20 extensive disease (n = 6) and A20 limited disease (n = 4). %ID/g values were calculated based on 1% injected dose standards and are depicted as box-and-whisker plot (min-max) application for anti-CD20 immunoPET could be prior to anti-CD20 radioimmunotherapy (RIT,   90 Y-ibritumomab tiuxetan, Zevalin®), where the antigen sink (tumour burden, spleen volume, amount of circulating B cells) greatly affects biodistribution and serum levels of the radioconjugate [14] . Monitoring response to therapy would be especially useful in B cell malignancies known to modulate CD20 cell surface expression.
